The therapeutic potential of novel cardiotonic agents

• Published in: Expert opinion on investigational drugs Vol. 12; no. 5; p. 735
• Main Author: Endoh, Masao
• Format: Journal Article
• Language: English
• Published: England 01.05.2003
• Subjects: 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors; Actin Cytoskeleton - metabolism; Adrenergic beta-Agonists - pharmacology; Adrenergic beta-Agonists - therapeutic use; Calcium - metabolism; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Failure - drug therapy; Heart Failure - metabolism; Heart Failure - physiopathology; Humans; Myocardium - metabolism; Myocardium - pathology; Phosphodiesterase Inhibitors - pharmacology; Phosphodiesterase Inhibitors - therapeutic use

During the course of treatment of heart failure patients, cardiotonic agents are inevitable for improvement of myocardial dysfunction. Clinically available agents, such as beta-adrenoceptor agonists and selective phosphodiesterase 3 inhibitors, act mainly via cyclic AMP/protein kinase A-mediated fac...